Its role in BRVO
is in the evaluation of retinal capillary non-perfusion areas, posterior segment neovascularisation, and macular oedema.
In general, macular branch RVO tends to have the best prognosis, followed by BRVO
, HRVO and then CRVO.
Currently, there are several pharmacological agents used for ME caused by BRVO
Results: In all follow-up months, there was a significant increase in BCVA in all RVO cases and in superotemporal BRVO
cases after the first injection of ranibizumab.
Independent sample t-test was applied to compare CRVO group with the BRVO
is defined as an eye that has retinal haemorrhage or other evidence of retinal vein occlusion and a dilated venous system in 1 quadrant or less of retina.
The positive CHMP recommendation is based on positive results from the double-masked, randomized, active-controlled phase 3 VIBRANT study in patients impacted by BRVO
In addition, the company has announced regulatory submissions for EYLEA in the US and EU for Macular Edema following BRVO
, which is the most significant threat to vision.
EYLEA (aflibercept) Injection's EMA submission is based on the positive Phase 3 VIBRANT trial, a double-masked, randomized, active-controlled study of patients with macular edema following BRVO
It means that Lucentis is the only therapy licensed to treat BRVO
20 patients of recent onset BRVO
who were seen during period of 2012 to 2014 were taken into study and followed for a period of 1 year.